Boehringer Ingelheim - Newspage 05.22.96
`
`http://www.boehringer-ingelheim.com/pr052296.htm
`
`Go
`
`OCT
`
`2 captures
`30 Oct 96 - 18 Jan 97
`
`1996 1997
`
`Page 1 of 1
`
`FEB
`
`Close
`
`Help
`
`1998
`
`JAN
`
`18
`
`22 May, 1996
`NEW TREATMENT FOR PROSTATE CANCER UNDER DEVELOPMENT
`Boehringer Ingelheim (BI) and British Technology Group (BTG) have signed an agreement granting BI an option to an exclusive licence
`to develop and market the new compound, CB7630, for treating androgen-dependent disease.
`
`CB7630 is mainly aimed at treating hormone-dependent prostate cancer. Prostate cancer is a common disease in the western countries
`with approximately 180,000 new cases each year. Because the incidence of prostate cancer increases with old age, effective treatment
`becomes a greater priority as the proportion of elderly in the population grows.
`
`In 75 - 80 % of cases, tumours of the prostate respond to hormonal therapy. Current clinical interest has focused on the concept of total
`blockade of the effects of both testicular and adrenal androgen production using an anti-androgen and LHRH agonist in combination.
`Early research suggests that CB7630 will cause rapid and profound suppression of serum testosterone levels and it is hoped that it will
`provide a convenient, single orally active drug for use as an alternative to combination therapy.
`
`CB7630 was discovered at the CRC Centre for Cancer Therapeutics at the Institute of Cancer Research (ICR), Sutton, UK. BTG funded
`much of the early development work and has filed patent applications in major territories worldwide. The Cancer Research Campaign
`plans to conduct a Phase I clinical trial of CB7630 at the Royal Marsden Hospital in London. If BI exercises its option, BI will take full
`responsibility for subsequent development.
`
`BTG will receive payments from BI linked to development milestones and a royalty based on sales. These revenues will be shared with
`the ICR and CRC under BTG's normal terms of business.
`
`Dr Peter Bailey, Head of Biosciences at BTG said "CB7630 is an important addition to BTG's portfolio of cancer drugs in development
`by major pharmaceutical companies worldwide. There is a clear need for improved treatment of prostate cancer. We are delighted to have
`reached agreement with Boehringer Ingelheim to take CB7630 forward."
`
`Prof. Rolf Krebs, Member of the Board of Managing Directors of Boehringer Ingelheim pointed out that Boehringer Ingelheim's interest
`in CB7630 was clearly in line with its strategic R&D focus of getting involved with innovative concepts in therapeutic areas with a high
`unmet medical need.
`
`Professor Gordon McVie, Director CRC Scientific Department said: "The Cancer Research Campaign has a major programme on the
`development of new anti-cancer drugs and has established, at the Institute of Cancer Research, the CRC centre for cancer therapeutics,
`which is the largest multi-disciplinary unit for anti-cancer drug development in the UK. ICR, in conjunction with the Royal Marsden
`NHS Trust constitutes a world-class centre of excellence for cancer research."
`
`BTG's business is the profitable commercialisation of technology. With nearly 50 years' experience of patenting and licensing technology
`to industry worldwide, BTG has considerable expertise in the protection, development and marketing of intellectual property. BTG holds
`around 10,000 patents and patent applications covering some 1400 inventions with approximately 500 licence agreements. It operates on
`an international basis with offices in the UK, USA, Japan and India.
`
`Boehringer Ingelheim is an international corporation with headquarters in Ingelheim, Germany, operating in the fields of pharmaceutical,
`biological, and chemical products. With about 160 companies, the Boehringer Ingelheim corporation is represented on every continent.
`With its own research, production and distribution facilities it ranks among the 20 major pharmaceutical companies worldwide.
`
`Contact:
`Dr Roger Harrison/Dr Peter Bailey
`British Technology Group
`55216 Ingelheim
`Tel.: + 44 - 171 - 403 6666
`Fax: + 44 - 171 - 403 7586
`
`Contact:
`Judith v. Gordon
`Boehringer Ingelheim GmbH
`55216 Ingelheim
`Tel.: + 49 - 6132 - 773582
`Fax: + 49 - 6132 - 776601
`
`Return to News Archive
`©Copyright 1996 : Boehringer Ingelheim GmbH
`
`http://web.archive.org/web/19970118070207/http://www.
`
`Contact: Webmaster
`
`
`
`JANSSEN EXHIBIT 2013
`Mylan v. Janssen IPR2016-01332
`
`